Rothschild & Co Asset Management US’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $6.46M | Buy |
139,517
+18,850
| +16% | +$873K | 0.1% | 159 |
|
|
2022
Q3 | $5M | Buy |
120,667
+71,494
| +145% | +$2.96M | 0.09% | 174 |
|
|
2022
Q2 | $2.93M | Buy |
49,173
+5,255
| +12% | +$314K | 0.05% | 223 |
|
|
2022
Q1 | $3.19M | Buy |
+43,918
| New | +$3.19M | 0.04% | 225 |
|
|
2020
Q3 | – | Sell |
-125,683
| Closed | -$9.83M | – | 315 |
|
|
2020
Q2 | $9.83M | Sell |
125,683
-16,187
| -11% | -$1.27M | 0.14% | 218 |
|
|
2020
Q1 | $6.3M | Sell |
141,870
-17,313
| -11% | -$769K | 0.1% | 240 |
|
|
2019
Q4 | $6.8M | Buy |
159,183
+51,593
| +48% | +$2.2M | 0.07% | 272 |
|
|
2019
Q3 | $4.6M | Buy |
107,590
+2,315
| +2% | +$99K | 0.05% | 284 |
|
|
2019
Q2 | $6.69M | Buy |
105,275
+49,735
| +90% | +$3.16M | 0.07% | 274 |
|
|
2019
Q1 | $3.85M | Buy |
55,540
+26,899
| +94% | +$1.87M | 0.04% | 296 |
|
|
2018
Q4 | $1.25M | Sell |
28,641
-266
| -0.9% | -$11.6K | 0.02% | 342 |
|
|
2018
Q3 | $2.21M | Sell |
28,907
-360
| -1% | -$27.5K | 0.02% | 334 |
|
|
2018
Q2 | $2.25M | Buy |
29,267
+5,998
| +26% | +$461K | 0.02% | 330 |
|
|
2018
Q1 | $1.19M | Sell |
23,269
-1,907
| -8% | -$97.2K | 0.01% | 339 |
|
|
2017
Q4 | $1.17M | Sell |
25,176
-1,883
| -7% | -$87.4K | 0.01% | 334 |
|
|
2017
Q3 | $1.44M | Sell |
27,059
-377
| -1% | -$20.1K | 0.02% | 318 |
|
|
2017
Q2 | $1.7M | Sell |
27,436
-1,448
| -5% | -$89.9K | 0.02% | 336 |
|
|
2017
Q1 | $1.96M | Sell |
28,884
-2,120
| -7% | -$144K | 0.02% | 322 |
|
|
2016
Q4 | $2.18M | Buy |
31,004
+25,404
| +454% | +$1.79M | 0.03% | 333 |
|
|
2016
Q3 | $397K | Buy |
5,600
+830
| +17% | +$58.8K | 0.01% | 506 |
|
|
2016
Q2 | $233K | Buy |
+4,770
| New | +$233K | ﹤0.01% | 549 |
|